These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15998832)

  • 1. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.
    Shaked Y; Emmenegger U; Man S; Cervi D; Bertolini F; Ben-David Y; Kerbel RS
    Blood; 2005 Nov; 106(9):3058-61. PubMed ID: 15998832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
    Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
    Yuan F; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
    Oncol Rep; 2015 Apr; 33(4):1753-62. PubMed ID: 25634241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts.
    Zhang M; Tao W; Pan S; Sun X; Jiang H
    Anticancer Drugs; 2009 Jun; 20(5):355-63. PubMed ID: 19318912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of nanoparticulate delivery systems in metronomic chemotherapy.
    Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
    Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer.
    Gille J; Spieth K; Kaufmann R
    J Dtsch Dermatol Ges; 2005 Jan; 3(1):26-32. PubMed ID: 16353746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
    Ng SS; Sparreboom A; Shaked Y; Lee C; Man S; Desai N; Soon-Shiong P; Figg WD; Kerbel RS
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4331-8. PubMed ID: 16857808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2008 Jan; 7(1):79-89. PubMed ID: 18202011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.
    Shaked Y; Bocci G; Munoz R; Man S; Ebos JM; Hicklin DJ; Bertolini F; D'Amato R; Kerbel RS
    Curr Cancer Drug Targets; 2005 Nov; 5(7):551-9. PubMed ID: 16305351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Tang TC; Man S; Lee CR; Xu P; Kerbel RS
    Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
    Zhang M; Chen C; Su F; Huang Z; Li X; Li X
    Technol Cancer Res Treat; 2017 Oct; 16(5):609-619. PubMed ID: 27573201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.